Total Payments
$2.6M
2024 Payments
$305,798
Companies
60
Transactions
4,384
Medicare Patients
3,597
Medicare Billing
$4.6M
Payment Breakdown by Category
Other$1.8M (69.9%)
Travel$338,116 (13.2%)
Consulting$336,357 (13.1%)
Food & Beverage$81,917 (3.2%)
Research$12,911 (0.5%)
Education$590.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.6M | 723 | 62.9% |
| Travel and Lodging | $338,116 | 682 | 13.2% |
| Consulting Fee | $336,357 | 140 | 13.1% |
| Honoraria | $178,449 | 105 | 7.0% |
| Food and Beverage | $81,917 | 2,698 | 3.2% |
| Unspecified | $12,911 | 12 | 0.5% |
| Education | $590.50 | 24 | 0.0% |
Payments by Type
General
$2.5M
4,372 transactions
Research
$12,911
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $532,889 | 634 | $0 (2024) |
| Celgene Corporation | $461,290 | 379 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $300,457 | 256 | $0 (2024) |
| ABBVIE INC. | $221,165 | 437 | $0 (2024) |
| Janssen Biotech, Inc. | $199,401 | 425 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $198,578 | 346 | $0 (2024) |
| Horizon Pharma plc | $110,097 | 152 | $0 (2018) |
| Horizon Therapeutics plc | $97,237 | 197 | $0 (2023) |
| Lilly USA, LLC | $82,039 | 185 | $0 (2024) |
| GlaxoSmithKline, LLC. | $71,193 | 151 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $305,798 | 560 | Amgen Inc. ($125,774) |
| 2023 | $240,262 | 559 | Janssen Biotech, Inc. ($67,624) |
| 2022 | $216,892 | 491 | Amgen Inc. ($70,598) |
| 2021 | $164,652 | 357 | Amgen Inc. ($55,612) |
| 2020 | $152,584 | 234 | Amgen Inc. ($64,574) |
| 2019 | $424,958 | 678 | Celgene Corporation ($124,589) |
| 2018 | $510,449 | 709 | Celgene Corporation ($128,345) |
| 2017 | $542,851 | 796 | Celgene Corporation ($208,056) |
All Payment Transactions
4,384 individual payment records from CMS Open Payments — Page 2 of 176
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $26.88 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/10/2024 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: Immunology | ||||||
| 12/09/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $29.74 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $10.99 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $4.01 | General |
| Category: Immunology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $2.83 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,655.00 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Travel and Lodging | In-kind items and services | $874.66 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Travel and Lodging | In-kind items and services | $420.99 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Travel and Lodging | In-kind items and services | $119.38 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,360.00 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $560.00 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $121.35 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: Dermatology | ||||||
| 12/04/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: Immunology | ||||||
| 12/04/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/03/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $612.00 | General |
| Category: Inflammation | ||||||
| 12/03/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $97.02 | General |
| Category: Inflammation | ||||||
| 12/03/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $20.37 | General |
| Category: Rheumatology | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | ILARIS (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: Inflammation | ||||||
| 11/25/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: Inflammation | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $5,790 | 9 |
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,980 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $3,142 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 759 | 195,271 | $3.3M | $1.6M |
| 2022 | 22 | 1,017 | 145,140 | $2.8M | $1.5M |
| 2021 | 23 | 1,026 | 69,984 | $1.9M | $1.0M |
| 2020 | 21 | 795 | 27,669 | $933,084 | $484,833 |
Total Patients
3,597
Total Services
438,064
Medicare Billing
$4.6M
Procedure Codes
80
All Medicare Procedures & Services
80 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 21 | 95,440 | $701,200 | $446,962 | 63.7% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 18 | 12,976 | $793,710 | $436,930 | 55.0% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 39 | 31,700 | $951,000 | $333,314 | 35.0% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 15 | 51,000 | $510,000 | $198,634 | 38.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 94 | 614 | $153,500 | $65,102 | 42.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 258 | 470 | $82,250 | $43,914 | 53.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 27 | 2,400 | $64,920 | $43,914 | 67.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 110 | 110 | $27,500 | $13,047 | 47.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 47 | 203 | $30,450 | $11,938 | 39.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 48 | 59 | $7,965 | $4,182 | 52.5% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 27 | 62 | $14,525 | $3,829 | 26.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 12 | 90 | $4,950 | $2,076 | 41.9% |
| 73120 | X-ray of hand, 2 views | Office | 2023 | 13 | 26 | $1,690 | $626.22 | 37.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 30 | 121 | $968.00 | $98.51 | 10.2% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 23 | 13,725 | $823,500 | $475,152 | 57.7% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 38 | 31,225 | $936,750 | $365,798 | 39.0% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2022 | 20 | 58,960 | $353,760 | $271,846 | 76.8% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 12 | 35,002 | $350,400 | $156,578 | 44.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 285 | 537 | $93,975 | $51,358 | 54.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 18 | 1,740 | $39,150 | $29,737 | 76.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 89 | 227 | $56,750 | $25,754 | 45.4% |
| J7318 | Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | Office | 2022 | 14 | 1,800 | $36,000 | $17,999 | 50.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 68 | 299 | $37,375 | $16,853 | 45.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 124 | 124 | $31,000 | $15,735 | 50.8% |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | Office | 2022 | 11 | 705 | $16,215 | $9,453 | 58.3% |
About Dr. Amar Majjhoo, MD
Dr. Amar Majjhoo, MD is a Rheumatology healthcare provider based in Saint Clair Shores, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255411039.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amar Majjhoo, MD has received a total of $2.6M in payments from pharmaceutical and medical device companies, with $305,798 received in 2024. These payments were reported across 4,384 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.6M).
As a Medicare-enrolled provider, Majjhoo has provided services to 3,597 Medicare beneficiaries, totaling 438,064 services with total Medicare billing of $4.6M. Data is available for 4 years (2020–2023), covering 80 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Saint Clair Shores, MI
- Active Since 10/16/2006
- Last Updated 11/24/2020
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1255411039
Products in Payments
- Otezla (Drug) $627,463
- Enbrel (Biological) $224,074
- SIMPONI ARIA (Biological) $194,631
- STELARA (Biological) $182,736
- COSENTYX (Biological) $182,650
- KRYSTEXXA (Biological) $157,080
- TREMFYA (Drug) $107,143
- KRYSTEXXA (Drug) $87,134
- RINVOQ (Biological) $83,208
- BENLYSTA (Biological) $71,178
- TALTZ (Drug) $63,908
- XELJANZ (Drug) $61,129
- KEVZARA SARILUMAB INJECTION (Biological) $48,346
- Humira (Biological) $45,472
- SAPHNELO (Biological) $37,301
- SKYRIZI (Biological) $33,620
- KEVZARA (Biological) $31,887
- ORENCIA (Biological) $28,451
- RAYOS (Drug) $23,019
- TAVNEOS (Drug) $13,476
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.